

INTERIM FORMULARY UPDATE

The following recommendations, made at the June 23, 2006 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:
None

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on the Sectional Reviews for Immunological Agents, Intravenous Solutions and Additives, and Nutritional Agents:

Generic Name	Brand Name	Dosage Form	Classification
Potassium phosphate	Neutra-Phos-K®		Immunological Agents
Calcium carbonate	Os-Cal, Titalac	600mg/200mg, 315mg/200mg	Gastrointestinal
Calcium citrate	Citracal	Tablet, 315 mg, 950 mg	Gastrointestinal
Vitamin D	Ergocalciferol, Calciferol, Drisdol	Tablet, 400 IU	Nutritional
Potassium chloride SA		Capsule 10mEq	Intravenous Solution
Vitamin D	Ergocalciferol, Calciferol, Drisdol	Capsule 0.25mcg, 0.5mcg	Nutritional

Dosage strength/formulations **recommended to be deleted** from the DADS/DSHS Drug Formulary based on the Sectional Reviews for Immunological Agents, Intravenous Solutions and Additives, and Nutritional Agents:

Generic Name	Brand Name	Dosage Form	Dosage Forms Still Available
Poliovirus vaccine, Inactivated	Ipol®	Injection, single dose	None
Rubella Virus Vaccine Live	Meruvax II ®	Injection, single dose	Measles, Mumps and Rubella Vaccine, Live (MMR II®)
Dextran	Gentran®, LMD®, Macrodex®, Rheomacrodex®	High molecular weight: 6% Dextran 75 in D4W, 6% Dextran 75 in NX, 6% Dextran 70 in NS Low molecular weight: 10% Dextran 40 in D5W, 10 % Dextran in NS	None

Dosage strength(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on the Agents for Review:

Generic Name	Brand Name	Dosage Form	Classification
potassium chloride			IV solutions and additives
sodium chloride			IV solutions and additives

Other recommendations:

- Removal of the volumes from Water for Injection, Dextrose 50% in Water and Lactated Ringers.

Previously, the Executive Formulary Committee requested input from the field regarding the following drugs proposed for deletion from the DADS/DSHS Drug Formulary. Based on the field's response, the following drugs are deleted from the Drug Formulary.

Products **deleted** from the DADS/DSHS Drug Formulary based on these previous Sectional Reviews:
None

Other **recommendation(s)/addition(s)/revisions(s)** to the DADS/DSHS Drug Formulary:

- To Change the Psychotropic Audit Guidelines for mesoridazine and thioridazine to match the Drug Formulary reserve category requirements.
- Send the Foster Children Guidelines to the field and the maximum dosage suggested in the document to be added to the Drug Formulary as maximum doses for this population and request feedback from the field regarding the use of these maximum doses in children and adolescent population.

Approved:



Steven P. Shon, M.D.
Medical Director

September 5, 2005
Date